Evidence map›Paper›PMID 41235019›Full record

ArticleCureus2025

Thyrotoxicosis Secondary to Gestational Trophoblastic Disease: A Rare Complication With Clinical Relevance.

Luis Antonio Rodriguez Arrieta, Duvan Alejandro Grisales Cano, Ana Maria Londoño Fonseca, Jorge Fernando Quintero Arrieta

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Luis Antonio Rodriguez ArrietaEndocrinology, Diabetes and Metabolism, Clínica de Inmunología y Genética, Medellín, COL.
Duvan Alejandro Grisales CanoInternal Medicine, Universidad Cooperativa de Colombia, Medellin, COL.
Ana Maria Londoño FonsecaMedicine, Unidad Central Del Valle del Cauca, Tuluá, COL.
Jorge Fernando Quintero ArrietaObstetrics and Gynecology, University of Cartagena, Cartagena, COL.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyrotoxicosis is a clinical syndrome defined by excessive exposure to circulating thyroid hormones, primarily triiodothyronine (T3) and thyroxine (T4). Its most common cause is hyperthyroidism, which is characterized by the increased production and secretion of hormones by the thyroid gland. However, it can also originate from extrathyroidal stimulation. An example is the disproportionately high production of human chorionic gonadotropin (HCG) in gestational trophoblastic disease (GTD), where excessive levels of this hormone induce thyrotoxicosis through cross-activation of thyroid-stimulating hormone (TSH) receptors. We present the case of a 23-year-old woman with a history of ectopic pregnancy who presented with persistent pregnancy symptoms. Clinical and laboratory studies confirmed GTD complicated by thyrotoxicosis, evidenced by markedly elevated levels of HCG, suppressed TSH, and elevated free T4. The imaging studies were consistent with an invasive mole with pulmonary metastasis. Management included antithyroid therapy with methimazole (thionamide), beta-blockers, and systemic chemotherapy, given the characteristics of the neoplasm. This case highlights the importance of a multidisciplinary approach in rare conditions such as GTD associated with thyrotoxicosis, where endocrine stabilization and targeted chemotherapy are the fundamental pillars for optimizing clinical and oncological prognosis.

Indexed as

beta-hcggestational thyroid dysfunctiongestational trophoblastic dieasehyperthyroidismthyrotoxicity

Identifiers

PMID41235019
PMCPMC12610917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.